Jake Nichols, PharmD, MBA: US WorldMeds: Employee (Ongoing)
Passage of the MAT Act eliminated guardrails that limit buprenorphine prescribing and has the potential to increase access to and reduce stigma surrounding OUD treatment. Pharmacists are key in ensuring access to and educating patients with OUD. In states where allowed, some pharmacists are prescribing buprenorphine under collaborative practice agreements. Attend this session to review pathophysiology, pharmacology and develop a plan for a patient in need of MOUD.
Learning Objectives:
Describe the prevalence and risk factors for opioid use disorder (OUD).
Explain the pathophysiology of OUD.
Compare and contrast evidence-based treatment options of OUD.
Construct a patient-specific pharmacotherapy plan for OUD.
